标签归档：氨曲南

氨曲南 标准品

发表于由

氨曲南 标准品

货号：
SA5160

品牌：
Jinpan

氨曲南 标准品

暂无详情
产品简介
EC EINECS 278-839-9
MDL MFCD00072145
别名 菌克单;
英文名称 Aztreonam
CAS 78110-38-0
分子式 C13H17N5O8S2
分子量 435.43
储存条件 2-8℃
纯度 HPLC≥98%
外观（性状） 白粉
单位 瓶
SMILES CC(C)(O/N=C(C1=CSC(N)=N1)C(N[C@H]2[C@H](C)N(S(=O)(O)=O)C2=O)=O)C(O)=O
规格 100mg

Aztreonam 氨曲南

发表于由

Aztreonam 氨曲南

货号：
IA0060

品牌：
Jinpan

Aztreonam 氨曲南

暂无详情
产品简介
MDL MFCD00072145
EC EINECS 278-839-9
别名 菌克单
CAS 78110-38-0
分子式 C13H17N5O8S2
分子量 435.43
纯度 HPLC≥98%
单位 瓶
生物活性 Aztreonam (also known as SQ 26776) is a synthetic monocyclic beta-lactam antibiotic, used to treat Gram-negative aerobic bacteria infection. It has a very high affinity for penicillin-binding protein 3 (PBP-3). Aztreonam causes significant suppression of human colony forming unit-erythroid (cfu-e), burst forming unit-erythroid (bfu-e) and colony forming unit-granulocyte macrophage (cfu-gm) at both peak and trough serum concentrations in human bone marrow cells. Aztreonam is hydrolyzed at measurable rates by class A beta-lactamases, a TEM-2 type penicillinase and the Proteus vulgaris cephalosporinase with a broad substraterange.[1-3]
In Vitro Aztreonam (SQ-26,776) is a synthetic monocyclic beta-lactam antibiotic (a monobactam), with the nucleus based on a simpler monobactam isolated from Chromobacterium violaceum. It was approved by the U.S. Food and Drug Administration in 1986. It is resistant to some beta-lactamases, but is inactivated by extended-spectrum beta-lactamases. Aztreonam has no useful activity against gram-positive or anaerobic microorganisms[1]. Aztreonam (SQ-26) is similar in action to penicillin. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidogly can crosslinking. It has a very high affinity for penicillin-binding protein 3 (PBP-3) and mild affinity for PBP-1a. Aztreonam (SQ-26) binds the penicillin-binding proteins of gram-positive and anaerobic bacteria very poorly and is largely ineffective against them. Aztreonam (SQ-26) is bactericidal but less so than some of the cephalosporins[2].
In Vivo Aztreonam (300 mg/kg) results in a significant decrease in the content of hepatic microsomal P450, while no significant change is observed in hepatic cytochrome b5 content and NADPH-cytochrome c (P450) reductase activity[3]
SMILES CC(C)(O/N=C(C1=CSC(N)=N1)C(N[C@H]2[C@H](C)N(S(=O)(O)=O)C2=O)=O)C(O)=O
靶点 Bacterial
数据来源文献 [1]. Kobayashi Y, et al. Synergy with aztreonam and arbekacin or tobramycin against Pseudomonas aeruginosa isolated from blood. J Antimicrob Chemother. 1992 Dec;30(6):871-2.

[2]. Guay DR, et al. Aztreonam, a new monobactam antimicrobial. Clin Pharm. 1985 Sep-Oct;4(5):516-26.
[3]. Ohmori S, et al. Pharmacology,?994, 48(3), 137-142.
规格 10mg 10mM*1mL (in DMSO) 50mg 100mg

是单环β-内酰胺抗生素，与青霉素结合蛋白3（PBP-3）有较高亲和力。